+ Follow CAPECITABINE Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 703067
[Title] => Roche's drug receives broader EU label for women with metastatic breast cancer
[Summary] => BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 564068
[Title] => Elderly colorectal cancer patients live cancer-free longer
[Summary] => The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
[DatePublished] => 2010-04-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 293346
[Title] => Study offers new hope for colon cancer cases
[Summary] => Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50.
Colon cancer is most common in people who smoke, eat a high-fat diet, and have a family history of colorectal cancer. However, majority of colon cancers occur in people older than 50 with no known risk factors other than age.
[DatePublished] => 2005-08-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 284181
[Title] => Oral chemotherapy: A unique treatment option
[Summary] => Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting.
In March 2005, Roche received approval from European authorities for capecitabine to be used as a post-surgery treatment in colon cancer patients.
[DatePublished] => 2005-06-30 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 275629
[Title] => Adjuvant treatment for colon cancer OK’d
[Summary] => European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer.
The drug has been shown to prolong cancer-free survival with less serious side effects compared to standard current treatment.
Adjuvant chemotherapy is a standard treatment approach for stage III colon cancer to destroy cancer cells remaining in the body after the tumor has been surgically removed.
[DatePublished] => 2005-04-28 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
CAPECITABINE
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 703067
[Title] => Roche's drug receives broader EU label for women with metastatic breast cancer
[Summary] => BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 564068
[Title] => Elderly colorectal cancer patients live cancer-free longer
[Summary] => The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
[DatePublished] => 2010-04-08 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 293346
[Title] => Study offers new hope for colon cancer cases
[Summary] => Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50.
Colon cancer is most common in people who smoke, eat a high-fat diet, and have a family history of colorectal cancer. However, majority of colon cancers occur in people older than 50 with no known risk factors other than age.
[DatePublished] => 2005-08-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[3] => Array
(
[ArticleID] => 284181
[Title] => Oral chemotherapy: A unique treatment option
[Summary] => Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting.
In March 2005, Roche received approval from European authorities for capecitabine to be used as a post-surgery treatment in colon cancer patients.
[DatePublished] => 2005-06-30 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 275629
[Title] => Adjuvant treatment for colon cancer OK’d
[Summary] => European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer.
The drug has been shown to prolong cancer-free survival with less serious side effects compared to standard current treatment.
Adjuvant chemotherapy is a standard treatment approach for stage III colon cancer to destroy cancer cells remaining in the body after the tumor has been surgically removed.
[DatePublished] => 2005-04-28 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
August 25, 2005 - 12:00am
